• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of dosage individualization of anti-tumor drugs based on therapeutic drug monitoring and pharmacokinetic-related gene expression

Research Project

Project/Area Number 17590131
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Medical pharmacy
Research InstitutionKumamoto University

Principal Investigator

MATSUMOTO Mitsuhiro  Kumamoto University, Faculty of Medical and Pharmaceutical Sciences, Assosiate Professor, 大学院医学薬学研究部, 助教授 (70253755)

Co-Investigator(Kenkyū-buntansha) SAITO Hideyuki  Kumamoto University Hospital, Professor Kumaaoto University, 医学部附属病院, 教授 (40225727)
WATANABE Hiroshi  Kumamoto University, School of Pharmacy, Associate frotessor, 薬学部, 講師 (70398220)
Project Period (FY) 2005 – 2006
Project Status Completed (Fiscal Year 2006)
Budget Amount *help
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2006: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2005: ¥2,000,000 (Direct Cost: ¥2,000,000)
Keywordsamurubic in / amurubicinol / therapeutic drug monitoring / pharmacokinetics / P-glycoprotein / 細胞膜輸送 / 薬剤耐性 / 個別化 / ファーマコダイナミクス
Research Abstract

Amrubicin, a synthetic 9-aminoanthracycline agent, was recently approved in Japan for treatment of small-cell lung cancer and non-small-cell lung cancer. Amrubicin is converted enzymatically to the C-13 hydroxy metabolite amrubicinol, which is active and possesses a cytotoxicity 10 to 100 times that of the parent drug. The purpose of this study was to charicterize the pharmacokinetics of amrubicin and its active metabolite amrubicinol. Amrubicin was administered on days 1-3 in 16 patients with advanced lung cancer. The pharmacokinetics analysis of amrubicin and amrubicinol was performed by high-performance liquid chromatography. When 45 mg/m amrubicin was administered in a bolus injection once every 24 hours for 3 consecutive days, the areas under the curves (0 to 72 hours) for amrubicin and amrubicinol were 13,490 and 2585 ng.h/mL, respectively. The apparent total clearance (CL_<app>) of amrubicin was 15.4 L/h. The area-under-the-curve ratio of amrubicinol to amrubicin was 15.1 +/-4.6% (mean +/-SD) at doses ranging from 30 to 45 mg/m. Interindividual variability in the enzymatic conversion of amrubicin to amrubicinol was small. In contrast, a large interindividual variability in the CL_<app> of amrubicin was observed (CV = 49.8%). The areas under the curves of amrubicin and amrubicinol seemed to be associated with the severity of hematologic toxicities. There is a possibility that monitoring of the plasma concentrations of amrubicin and amrubicinol may provide an efficient tool for establishing the optimal dosage of amrubicin in each patient. Furthermore, we found that both amrubicin and amrubicinol are substrates of P-gp. Additionally, the antitumor effects of amrubicin might be affected by P-gp in lung cancer cells. Further studies are warranted to clarify the contribution of P-gp in the antitumor activity and pharmacokinetics of amrubicin.

Report

(3 results)
  • 2006 Annual Research Report   Final Research Report Summary
  • 2005 Annual Research Report
  • Research Products

    (27 results)

All 2007 2006 2005

All Journal Article (27 results)

  • [Journal Article] Variants in the SLCO1B3 gene : interethnic distribution and association with paclitaxel pharmacokinetics.2007

    • Author(s)
      Smith NF, Marsh S, Scott-Horton TJ, et al.
    • Journal Title

      Clin. Pharmacol. Ther. 81(1)

      Pages: 76-82

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Involvement of Indoxyl Sulfate in Renal and Central Nervous System Toxicities During Cisplatin-Induced Acute Renal Failure.2007

    • Author(s)
      Iwata K, Watanabe H, Morisaki T, et al.
    • Journal Title

      Pharm. Res. (印刷中)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure.2007

    • Author(s)
      Matsuzaki T, Watanabe H, Yoshitome K, et al.
    • Journal Title

      Kidney Int. (印刷中)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Annual Research Report 2006 Final Research Report Summary
  • [Journal Article] Sparreboom A. Variants in the SLCO1B3 gene : interethnic distribution and association with paclitaxel pharmacokinetics.2007

    • Author(s)
      Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL
    • Journal Title

      Clin Pharmacol Ther. 81(1)

      Pages: 76-82

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Involvement of Indoxyl Sulfate in Renal and Central Nervous System Toxicities During Cisplatin-Induced Acute Renal Failure.2007

    • Author(s)
      Iwata K, Watanabe H, Morisaki T, Matsuzaki Ohmura T, Hamada A, Saito H.
    • Journal Title

      Pharm Res. (in press)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Downregulation of organic anion transporters in rat kidney under ischemialreperfusion-induced acute renal failure.2007

    • Author(s)
      Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, Kohda Y, Tomita K, Inui K, Saito H.
    • Journal Title

      Kidney Int. (in press)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Involvement of Indoxyl Sulfate in Renal and Central Nervous System Toxicities During Cisplatin-Induced Acute Renal Failure.2007

    • Author(s)
      Iwata K, Watanabe H, Morisaki T, et al.
    • Journal Title

      Pharm.Res. (印刷中)

    • Related Report
      2006 Annual Research Report
  • [Journal Article] Phase I and pharmacokinetic study of amrubicin,a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.2006

    • Author(s)
      Okamoto I, Hamada A, Matsunaga Y, et al.
    • Journal Title

      Cancer Chemother. Pharmacol. 57(3)

      Pages: 282-288

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.2006

    • Author(s)
      Yokoo K, Watanabe H, Hamada A, et al.
    • Journal Title

      Clin. Pharmacol. Ther. 80(4)

      Pages: 422-424

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Chain Length-dependent Binding of Fatty Acid Anions to Human Serum Albumin Studied by Site-directed Mutagenesis.2006

    • Author(s)
      Kragh-Hansen U, Watanabe H, Nakajou K, et al.
    • Journal Title

      J. Mol. Biol. 363(3)

      Pages: 702-712

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.2006

    • Author(s)
      Okamoto I, Hamada A, Matsunaga Y, Sasaki J, Fujii S, Uramoto H, Yamagata H, Mori I, Kishi H, Semba H, Saito H.
    • Journal Title

      Cancer Chemother Pharmacol. 57(3)

      Pages: 282-288

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.2006

    • Author(s)
      Matsunaga Y, Hamada A, Okamoto I, Sasaki J, Moriyama E, Kishi H, Matsumoto M, Hira A, Watanabe H, Saito H.
    • Journal Title

      Ther Drug Monit. 28(1)

      Pages: 76-82

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.2006

    • Author(s)
      Yokoo K, Watanabe H, Hamada A, Masa K, Saito H, Terazaki H, Sasaki Y.
    • Journal Title

      Clin Pharmacol Ther. 80(4)

      Pages: 422-424

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Chain Length-dependent Binding of Fatty Acid Anions to Human Serum Albumin Studied by Site-directed Mutagenesis.2006

    • Author(s)
      Kragh-Hansen U, Watanabe H, Nakajou K, Iwao Y, Otagiri M.
    • Journal Title

      J Mol Biol. 363(3)

      Pages: 702-712

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.2006

    • Author(s)
      Yokoo K, Watanabe H, Hamada A, et al.
    • Journal Title

      Clin.Pharmacol.Ther. 80 (4)

      Pages: 422-424

    • Related Report
      2006 Annual Research Report
  • [Journal Article] Chain Length-dependent Binding of Fatty Acid Anions to Human Serum Albumin Studied by Site-directed Mutagenesis.2006

    • Author(s)
      Kragh-Hansen U, Watanabe H, Nakajou K, et al.
    • Journal Title

      J.Mol.Biol. 363(3)

      Pages: 702-712

    • Related Report
      2006 Annual Research Report
  • [Journal Article] Pharmacokinetics of Amrubicin and Its Active Metabolite Amrubicinol in Lung Cancer Patients.2006

    • Author(s)
      Matsunaga Y, Hamada A, Okamoto I, et al.
    • Journal Title

      Ther.Drug.Monit. 28(1)

      Pages: 76-82

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Daily expression of clock genes in whole blood cells in healthy subjects and a patient with circadian rhythm sleep disorder.2005

    • Author(s)
      Takimoto M, Hamada A, Tomoda A, et al.
    • Journal Title

      Am. J. Physiol. Regul. Integr. Comp. Physiol. 289(5)

      Pages: 1237-1279

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.2005

    • Author(s)
      Okamoto I, Moriyama E, Fujii S, et al.
    • Journal Title

      Jpn. J. Clin. Oncol. 35(4)

      Pages: 188-194

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.2005

    • Author(s)
      Hamada A, Aoki A, Terazaki H, et al.
    • Journal Title

      Ther. Drug. Monit. 27(4)

      Pages: 536-538

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Pharmacokinetics of Amrubicin and Its Active Metabolite Amrubicinol in Lung Cancer Patients.2005

    • Author(s)
      Matsunaga Y, Hamada A, Okamoto I, et al.
    • Journal Title

      Ther. Drug. Monit. 27(4)

      Pages: 536-538

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Daily expression of clock genes in whole blood cells in healthy subjects and a patient with circadian rhythm sleep disorder.2005

    • Author(s)
      Takimoto M, Hamada A, Tomoda A, Ohdo S, Ohmura T, Sakato H, Kawatani J, Jodoi T, Nakagawa H, Terazono H, Koyanagi S, Higuchi S, Kimura M, Tukikawa H, Irie S, Saito H, Miike T.
    • Journal Title

      Am J Physiol Regul Integr Comp Physiol. 289(5)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.2005

    • Author(s)
      Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, Kiyofuji C, Imamura F, Mori T, Matsumoto M.
    • Journal Title

      Jpn J Clin Oncol. 35(4)

      Pages: 188-94

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.2005

    • Author(s)
      Hamada A, Aoki A, Terazaki H, Ito K, Yokoo K, Sasaki Y, Saito H.
    • Journal Title

      Ther Drug Monit. 27(4)

      Pages: 536-538

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.2005

    • Author(s)
      Okamoto I, Moriyama E, Fujii S, et al.
    • Journal Title

      Jpn.J.Clin.Oncol. 35(4)

      Pages: 188-194

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.2005

    • Author(s)
      Hamada A, Aoki A, Terazaki H, et al.
    • Journal Title

      Ther.Drug.Monit. 27(4)

      Pages: 536-538

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.2005

    • Author(s)
      Okamoto I, Hamada A, Matsunaga Y, et al.
    • Journal Title

      Cancer Chemother.Pharmacol. 57(3)

      Pages: 282-288

    • Related Report
      2005 Annual Research Report

URL: 

Published: 2005-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi